A new study highlights the Cardio-Ankle Vascular Index (CAVI) as a powerful tool for predicting COPD progression and outcomes ...

Ghana's roadmap to a safer future through Tobacco Harm Reduction: Reflections on the Lives Saved Report, Nigeria and Kenya ...

GSK’s Nucala receives US FDA approval for use in adults with chronic obstructive pulmonary disease: London, UK Saturday, May 24, 2025, 11:00 Hrs [IST] GSK plc announced that the ...

FDA approves Nucala as add-on therapy for COPD with high eosinophils, offering new hope by reducing flare-ups in patients ...

Myanmar has faced substantial disruption, with impacts on respiratory health, in the aftermath of a devastating 7·7 magnitude earthquake. The country was hit on March 28, 2025, along with its ...

St. Louis can either use the disaster as an opportunity to commit to the safety of all its residents, or it can continue a ...

By Stephanie Brown HealthDay ReporterFRIDAY, May 23, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...

GSK stock dips 0.6% after six-session gain streak. EU panel backs Blenrep for multiple myeloma, while FDA expands asthma ...

Mepolizumab has had a bumpy road to arriving at its indication in COPD. An FDA advisory committee in 2018 declined to ...

The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...

Approval of Nucala marks the first biologic approved for chronic obstructive pulmonary disease patients with blood eosinophil counts as low as ≥150 cells/μL.

Many power plants benefiting from exemptions rank among the nation’s worst polluters. The Trump administration says cheaper ...